Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamazym Aftercare in Alpha-Mannosidosis
NCT01908712Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Aug 2013
- Primary completion
- Sep 2022
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of velmanase alfa in alpha-mannosidosis, sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Change from baseline in Adverse events at 3 years and Change from baseline in Lamazym antibodies at 3 years. Started Aug 2013; status: completed.
02
Drugs
velmanase alfa
03
Conditions
alpha-mannosidosis
Beyond the preview
Go deeper on NCT01908712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01908712.